Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|Hyperinsulinism Hypoglycemia Insulinoma||Other: 111In-exendin-4 imaging||Phase 1|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||The Physiology of Glucagon-like-peptide-1 Receptor Expression in Patients With Endogenous Hyperinsulinism - Correlation With Histopathology|
- Detection of insulinomas, cure rate [ Time Frame: one year ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||November 2007|
|Study Completion Date:||December 2011|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Other: 111In-exendin-4 imaging
Insulinomas arise from pancreatic cells and are the most frequent hormone-active tumours of the pancreas. Insulinomas produce insulin and can become life threatening if they cannot be localised and removed surgically. Complete tumour resection cures most patients, hence surgery is the treatment of choice for begin and malignant insulinomas. The potential for surgical cure necessitates accurate tumour localisation before surgery because preoperative imaging facilitates the detection of small localised, multiple and metastatic insulinomas. However, the successful localisation of insulinomas is an challenging problem since approximately 30% of insulinomas cannot be visualised radiographically.
A novel nuclear medicine scanning method using radioactive exendin-4 (111In-exendin-4) has recently been developed for imaging of insulinomas. 111In-exendin-4 accumulates specifically in insulinoma cells via the glucagon-like peptide-1 (GLP-1) receptor. The accumulation of 111In-exendin-4 can be visualised by the use of a special camera (Single Photon Emission Computed Tomography (SPECT) camera) that detects radioactivity and lights up tumours as hot spots.
The decision to perform surgery is independent of this study. If surgery is performed a small sample of the tumor will be used for identifying the sites where 111In-exendin-4 binds to the tumor.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00937079
|University Hospital Basel, Institute of Nuclear Medicine|
|Basel, Basel-Stadt, Switzerland, CH-4031|
|Principal Investigator:||Damian Wild, MD||University Hospital, Basel, Switzerland|